Teva: A Pill Too Bitter For This Old Investor

by

Alright, folks, settle in. We’re talking Teva Pharmaceutical (TEVA +0.24%). Now, I’ve been kicking tires on stocks since before your grandfather was born, and let me tell you, this one? This one gives me a rash. A perfectly reasonable rash, mind you, but a rash nonetheless. Some folks see a bargain, a turnaround story. I see a potential headache. And at my age, I’ve had enough of those, thank you very much.

What Does Teva Pharmaceutical Do, Anyway?

Historically, Teva was the king of the copycat drug business. You know, the guys who wait for the big pharmaceutical companies to spend billions developing a miracle cure, then swoop in and make a perfectly acceptable version for a fraction of the price? It’s a beautiful business, really. Like waiting for someone else to build the castle, then politely asking to live in it. They call it ‘generics.’ I call it shrewd. But even shrewd has its limits.

See, the original guys – the innovators – get a limited run, a patent, to recoup their investment. Then boom, Teva and its brethren move in. It’s the pharmaceutical equivalent of a vulture picking at a perfectly good, albeit temporarily incapacitated, carcass. Not elegant, but profitable. Usually.

The Generics Game is Getting…Crowded

Now, everybody and their cousin decided they wanted a piece of this action. Suddenly, it’s less like a peaceful vulture convention and more like a Black Friday sale at a pharmacy. Competition, naturally, went up. Profits? Not so much. It’s like trying to sell hot dogs at a sausage convention. You can do it, but you’ll be fighting for every bite.

Teva, bless their ambitious little hearts, decided to move upmarket. They started chasing the complicated generics – the ones that require a Ph.D. just to look at the formula. It’s a smart move, in theory. Like switching from selling peanuts at the ballpark to selling caviar. More difficult, more expensive, and a much higher chance of ending up with a face full of shellfish.

Loading widget...

But here’s where my indigestion really starts. They’re not just sticking to the tricky generics. Oh no. They’re trying to invent drugs. Original, brand-spanking-new drugs. Now, I admire the chutzpah. It’s like a guy who’s made a career out of repairing shoes suddenly deciding he’s going to design a spaceship. Possible? Sure. Likely? Let’s just say I’m not holding my breath.

Even the big boys – the Pfizers and the Mercks – have flops. Pfizer, for example, recently scrapped a weight loss drug. A weight loss drug! The irony is thicker than a milkshake. They quickly pivoted, of course – bought a company with a promising alternative and made a deal with another. They’re nimble. They have deep pockets. Teva? I’m not convinced they can do the same quick-change act if their pipeline hits a snag. It’s like trying to teach a walrus to tap dance.

Look, I’m at that stage of life where I prefer my investments to be about as exciting as watching paint dry. I understand why some folks are drawn to Teva’s gamble. It’s a high-risk, potentially high-reward play. But for me? Too much risk. Too much competition. I’ll stick to companies that are a little less…adventurous. Maybe, just maybe, after a few years of solid results, I’ll revisit. But for now, I’m prescribing myself a healthy dose of caution. And perhaps a nap.

Read More

2026-02-28 02:33